C4 Therapeutics, Inc.
CCCC · XNASCIK 1662579fmd_1G5CNQH9XQ04400TAMEK746KQMManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2019 to Sep 30, 2026, 29 periods
| Line item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Total revenues | – | – | 46 | 31 | 21 | 36 | 36 |
| Research and development | 48 | 78 | 95 | 118 | 118 | 111 | 104 |
| Total operating expenses | 57 | 94 | 128 | 161 | 160 | 155 | 151 |
| Operating income | (35) | (60) | (82) | (130) | (139) | (120) | (115) |
| Interest and investment income | 2 | 0 | 0 | 4 | 10 | 14 | 10 |
| Other non-operating income (expense) | 2 | (7) | (2) | 1 | 8 | 14 | 10 |
| Income before taxes | (33) | (67) | (84) | (128) | (131) | (105) | (105) |
| Income tax expense | 1 | (1) | 0 | 0 | 1 | 0 | 0 |
| Net income from continuing operations | (34) | (66) | (84) | (128) | (132) | (105) | (105) |
| Net income | (34) | (66) | (84) | (128) | (132) | (105) | (105) |
| Net income to common shareholders | (43) | (66) | (84) | – | – | – | – |